Primary Outcome Measures
Disease-free Survival (DFS), as Assessed by the Investigator [Time Frame: From the date of randomization until the first DFS event, up to approximately 5 years] [Designated as safety issue: ]
Secondary Outcome Measures
Overall Survival (OS) [Time Frame: From the date of randomization until death due to any cause up to approximately 8 years] [Designated as safety issue: ]
Plasma Concentration of Alectinib [Time Frame: Predose (2 hours) at Baseline, Week 3, 6, 9, 12, 24, 36, 48, 60, 72, 84, and 96] [Designated as safety issue: ]
Plasma Concentration of Alectinib metabolite [Time Frame: Predose (2 hours) at Baseline, Week 3, 6, 9, 12, 24, 36, 48, 60, 72, 84, and 96] [Designated as safety issue: ]
Percentage of Participants with Adverse Advent [Time Frame: From the date of randomization up to approximately 2 years] [Designated as safety issue: ]